KEYLearning Hub
Optimise treatment outcome for your
1L aRCC patients treated with
KEYTRUDA® (pembrolizumab) plus
KISPLYX® (lenvatinib)
Optimise treatment outcome for your
1L aRCC patients treated with
KEYTRUDA® (pembrolizumab) plus
KISPLYX® (lenvatinib)
KEYTRUDA® (pembrolizumab) Prescribing Information for Great Britain & Northern Ireland [External links]
KISPLYX® (lenvatinib) Prescribing information for Great Britain & Northern Ireland [External link]
Welcome to the advanced RCC KEYLearning Hub, learn from your fellow clinicians below as they describe their experiences of managing patients being treated with KEYTRUDA in combination with KISPLYX.
KEYTRUDA, in combination with KISPLYX, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.1
Please refer to the individual product SmPCs before prescribing.
Dr Ricky Frazer, Consultant Medical Oncologist at the Velindre Cancer Centre in Cardiff presents a case study of a 57 year old male with advanced renal cell carcinoma, treated with KEYTRUDA in combination with KISPLYX. This patient was diagnosed with multiple metastases (lung mets and large bone mets) and was classified as IMDC intermediate risk.
Dr Ricky Frazer, describes his treatment decision making, management of adverse events and the patient’s treatment outcome.
This content is intended to be viewed on laptop/desktop only, for optimal view please watch the video in full-screen using the button in the bottom right.
KEYTRUDA® (pembrolizumab) Prescribing Information for Great Britain & Northern Ireland [External links]
KISPLYX® (lenvatinib) Prescribing information for Great Britain & Northern Ireland [External link]
Filmed: May 2023 | Length: 10:31
Dr John McGrane, Consultant Clinical Oncologist at the Royal Cornwall Hospitals NHS Trust in Truro presents a case study of a 62 year old male with advanced renal cell carcinoma, treated with KEYTRUDA in combination with KISPLYX. This patient was diagnosed with sarcomatoid features and bone metastases and was classified as IMDC intermediate risk.
Dr John McGrane, describes his treatment decision making, management of adverse events and the patient’s treatment outcome.
This content is intended to be viewed on laptop/desktop only, for optimal view please watch the video in full-screen using the button in the bottom right.
KEYTRUDA® (pembrolizumab) Prescribing Information for Great Britain & Northern Ireland [External links]
KISPLYX® (lenvatinib) Prescribing information for Great Britain & Northern Ireland [External link]
Filmed: June 2023 | Length: 11:22
Dr Richard Griffiths, Consultant Medical Oncologist at the Clatterbridge Cancer Centre NHS Foundation Trust presents a case study of a 61 year old female with advanced renal cell carcinoma, treated with KEYTRUDA in combination with KISPLYX. This patient was diagnosed with spinal metastases, pulmonary and adrenal nodules and was classified as IMDC intermediate risk.
Dr Richard Griffiths, describes his treatment decision making, management of adverse events and the patient’s treatment outcome.
This content is intended to be viewed on laptop/desktop only, for optimal view please watch the video in full-screen using the button in the bottom right.
KEYTRUDA® (pembrolizumab) Prescribing Information for Great Britain & Northern Ireland [External links]
KISPLYX® (lenvatinib) Prescribing information for Great Britain & Northern Ireland [External link]
Filmed: June 2023 | Length: 09:23
KEYTRUDA Prescribing Information for Great Britain & Northern Ireland
KISPLYX Prescribing information for Great Britain & Northern Ireland
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website
Loading...
This section of MSD Connect is an online portal containing promotional information about MSD pharmaceutical products, therapy area materials and professional resources and is intended for UK Healthcare Professionals.
To contact us please telephone 0208 154 8000 or email medicalinformationuk@msd.com | Privacy Policy | Terms of Use
GB-NON-07197 | Date of Preparation: August 2023
Merck Sharp & Dohme (UK) Limited Registered Office: 120 Moorgate, London, EC2M 6UR, United Kingdom.
Registered in England No. 233687 Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Merck Sharp & Dohme (UK) Limited (Tel: 0208 154 8000)
This section of the website contains promotional information intended for UK Healthcare Professionals only. If you are not a UK healthcare professional, please click here. GB‑NON‑07725 | Date of Preparation: August 2023